

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 October 2016, 14 May 2017, 6 June 2017 and 19 September 2017 in relation to the research and development results of a chimeric antigen receptor (“**CAR**”) T cell therapeutic product LCAR-B38M in an Investigator Initiated Clinical Study conducted by four 3A hospitals in China, which was supported by Nanjing Legend Biotechnology Co., Ltd.* 南京傳奇生物科技有限公司 (“**Nanjing Legend**”), a controlled subsidiary of the Company as of the date of this announcement.

LCAR-B38M is a biparatopic chimeric antigen receptor T cell (CAR-T) therapy, directed against B-cell maturation antigen (BCMA). The dual-epitope BCMA binding moieties confer high avidity binding and distinguish LCAR-B38M from other BCMA CAR constructs. Preliminary results of LCAR-B38M in patients with relapsed/refractory (R/R) multiple myeloma (MM) showed encouraging efficacy and manageable safety profile.

The Phase 1, open-label study evaluates LCAR-B38M, a CAR-T therapy directed against BCMA, in subjects with R/R MM. Fifty-seven subjects were enrolled in The Second Affiliated Hospital of Xi’an Jiaotong University. The long term follow up data of these 57 subjects (with a cut-off date of 25th June 2018) has been selected as an oral presentation at the 2018 American Society of Hematology (ASH) Annual Meeting, December 1-4 San Diego, California. The detailed data (abstract #955) will be presented on Monday, December 3.

The remaining patients were enrolled in Shanghai Ruijin Hospital, Jiangsu Province People’s Hospital and Shanghai Changzheng Hospital. The safety and efficacy profiles observed for these patients are consistent with those treated in The Second Affiliated Hospital of Xi’an Jiaotong University, and the data will be published separately by the investigators.

“There have been limited treatment options available to patients with R/R Multiple Myeloma, underlining a need for new options beyond currently available therapies”, said study author Wanhong Zhao, MD, PhD, an Associate Director of Hematology at The Second Affiliated Hospital of Xi’an Jiaotong University in Xi’an, China. “BCMA is an important target in multiple myeloma. We are pleased to share updated data from our clinical trial investigating LCAR-B38M during the ASH Annual Meeting. LCAR-B38M is an investigational, dual-epitope CAR-T cell therapy and could provide a potential meaningful therapeutic option that may achieve and maintain deep & durable responses with a generally tolerable safety profile”.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise in caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 1 November 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*